156 related articles for article (PubMed ID: 3002388)
1. Inhibition of human platelet cyclic AMP phosphodiesterase and of platelet aggregation by a hemisynthetic flavonoid, amentoflavone hexaacetate.
Beretz A; Briançon-Scheid F; Stierlé A; Corre G; Anton R; Cazenave JP
Biochem Pharmacol; 1986 Jan; 35(2):257-62. PubMed ID: 3002388
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cyclic AMP phosphodiesterase activity of human blood platelet membrane by ADP.
Kahn NN; Sinha AK
Biochim Biophys Acta; 1989 Aug; 984(1):113-8. PubMed ID: 2548620
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
[No Abstract] [Full Text] [Related]
4. Imidazoquinoline derivatives: potent inhibitors of platelet cAMP phosphodiesterase which elevate cAMP levels and activate protein kinase in platelets.
Seiler S; Gillespie E; Arnold AJ; Brassard CL; Meanwell NA; Fleming JS
Thromb Res; 1991 Apr; 62(1-2):31-42. PubMed ID: 1649498
[TBL] [Abstract][Full Text] [Related]
5. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
Ruppert D; Weithmann KU
Life Sci; 1982 Nov; 31(19):2037-43. PubMed ID: 6294426
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of rabbit platelet phosphodiesterase activity and aggregation by calcium channel blockers.
Moore JB; Fuller BL; Falotico R; Tolman EL
Thromb Res; 1985 Nov; 40(3):401-11. PubMed ID: 2417362
[TBL] [Abstract][Full Text] [Related]
7. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
Lam SC; Guccione MA; Packham MA; Mustard JF
Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543
[TBL] [Abstract][Full Text] [Related]
8. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
9. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
10. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets.
Simpson AW; Reeves ML; Rink TJ
Biochem Pharmacol; 1988 Jun; 37(12):2315-20. PubMed ID: 2455518
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233.
Dawicki DD; Agarwal KC; Parks RE
Thromb Res; 1986 Jul; 43(2):161-75. PubMed ID: 3016942
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human platelet aggregation by dihydropyrano- and dihydrofuranocoumarins, a new class of cAMP-phosphodiesterase inhibitors.
Thastrup O; Knudsen JB; Lemmich J; Winther K
Biochem Pharmacol; 1985 Jun; 34(12):2137-40. PubMed ID: 2988567
[TBL] [Abstract][Full Text] [Related]
13. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
Beretz A; Stierle A; Anton R; Cazenave JP
Biochem Pharmacol; 1982 Nov; 31(22):3597-600. PubMed ID: 6295405
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic nipecotamide increases cyclic AMP levels and inhibits protein phosphorylation in human platelets.
Handa RK; Dillingham EO; Gollamudi R
Life Sci; 1995; 57(10):983-8. PubMed ID: 7643723
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.
Azuma H; Takashima Y; Ishikawa M; Yamakado T
Jpn J Pharmacol; 1984 Feb; 34(2):159-70. PubMed ID: 6205194
[TBL] [Abstract][Full Text] [Related]
16. Effects of adenosine on levels of adenosine cyclic 3',5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation.
Haslam RJ; Rosson GM
Mol Pharmacol; 1975 Sep; 11(5):528-44. PubMed ID: 170501
[No Abstract] [Full Text] [Related]
17. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase.
Mikashima H; Nakao T; Goto K; Ochi H; Yasuda H; Tsumagari T
Thromb Res; 1984 Sep; 35(5):589-94. PubMed ID: 6091293
[TBL] [Abstract][Full Text] [Related]
18. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography.
Umekawa H; Tanaka T; Kimura Y; Hidaka H
Biochem Pharmacol; 1984 Nov; 33(21):3339-44. PubMed ID: 6093810
[TBL] [Abstract][Full Text] [Related]
19. Human platelet aggregation and cAMP system--cAMP level, adenyl cyclase, phosphodiesterase.
Wang TY; Hussey CV; Sasse EA; Fobian JE
Ann Clin Lab Sci; 1978; 8(5):403-12. PubMed ID: 213009
[TBL] [Abstract][Full Text] [Related]
20. Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences.
Agarwal KC; Buckley RS; Parks RE
Thromb Res; 1987 Jul; 47(2):191-200. PubMed ID: 2821650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]